Additional Information

Description

Afluria® 2025–2026 (Flu-107) is an inactivated quadrivalent influenza vaccine presented in 0.5 mL prefilled syringes. It is formulated to provide active immunization against influenza A and B viruses predicted to circulate during the 2025–2026 influenza season. The vaccine contains purified hemagglutinin antigens from two A strains and two B strains, consistent with annual WHO recommendations.

This formulation is suitable for individuals aged 6 months and older. Each dose is administered as a 0.5 mL intramuscular injection, preferably into the deltoid muscle for adults or the anterolateral thigh for young children. Afluria® does not contain any live virus and cannot cause influenza. The prefilled syringes are preservative-free and single-use, designed to reduce risk of contamination and improve administration efficiency.

Mild adverse reactions may include localized pain, swelling, redness, fatigue, and headache. Less commonly, individuals may experience fever, muscle pain, or malaise. Administration should be avoided in individuals with known hypersensitivity to any vaccine component or those with a history of severe allergic reaction to a previous influenza vaccine.